Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals, Inc. (LBPH)
Company Research
Source: Business Wire
DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadlyInitial sites activated with additional sites expected to be activated in the coming weeks LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older.“The initiation of our second global Phase 3 clinical trial, DEEp OCEAN in DEEs, is a significant milestone for Longboard and the entire DEE community. As the first pivotal trial of its kind to study DEEs broadly with the goal of achieving an indication for seizures associated with DEEs, DEEp OCEAN has the ability to address a crucial unmet need,” stated C
Show less
Read more
Impact Snapshot
Event Time:
LBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBPH alerts
High impacting Longboard Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LBPH
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of ShareholdersPR Newswire
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesBusiness Wire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of ShareholdersPR Newswire
- LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPHBusiness Wire
LBPH
Earnings
- 11/7/24 - Miss
LBPH
Sec Filings
- 12/2/24 - Form 4
- 12/2/24 - Form 4
- 12/2/24 - Form 4
- LBPH's page on the SEC website